← GrantMatch
HomeGrants

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 -

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.

AgencyNational Institutes of Health
StatusPosted
Opportunity numberPAR-25-266
Posted date12/02/2024
Application deadlineNov 16, 2027 12:00:00 AM EST
Award ceiling200,000
Award floornone
Estimated total funding200,000
Who can applyOther Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); R
Assistance Listing (CFDA)93.865
DescriptionThis FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Agency contactgrantsinfo@nih.gov
Official listinghttps://www.grants.gov/search-results-detail/357487

🔍 Search all grants →